Event Details

Nanobiotix will host a conference call and webcast on Monday May 5th, 2025, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer and chairman of the executive board of Nanobiotix, will discuss the full results from the Phase 1 study, conducted by MD Anderson, evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. 
Conference call link (dial-in): https://register-conf.media-server.com/register/BIe0a6552710cc46d79ed0dd68d1cc82cc